Healthcare Resources Utilization and Sick Leave Experience of Major Depressive Disorder Patients Initiating Treatment with Antidepressants in Germany and Spain
Author(s)
Bonelli A1, Cattaneo A1, Comandini A1, Di Dato G1, Puricelli F1, Heiman F2, Pegoraro V3, Palao D4, ROCA Bennasar MA5, Volz HP6, Kasper S7
1Angelini Pharma S.p.A., Rome, Italy, 2IQVIA, MILANO, Italy, 3IQVIA, Milan, Italy, 4University Hospital Parc Taulí Sabadell, Sabadell, Spain, 5Institut Universitari d' Investigació en Ciències de la Salut, Idisba, Rediapp, University of Balearic Islands, Palma de Mallorca, Spain, 6Hospital for Psychiatry, Werneck, Werneck, Germany, 7Medical University of Vienna, Vienna, Austria
Presentation Documents
OBJECTIVES: To describe major depressive disorder (MDD) patients initiating antidepressants (ADs) treatment in terms of healthcare resources utilization (HRU) and sick leave (SL) experience by therapeutic approach METHODS: This was a real-world evidence retrospective study using general practitioners (GPs) and specialists (psychiatrists and neurologists) data from IQVIA German Disease Analyzer and Spanish Longitudinal Patient Database. 19-64 years-old MDD patients initiating treatment with ADs during ‘July 2016 - June 2018’ were selected and followed-up for a 12-month period. Patients were classified depending on the therapeutic approach as: 1) AD monotherapy (ADMONO - no ADs molecules different from the one received at treatment start during follow-up) or 2) AD combination/switch/add-on patients (ADCOM - more than one AD molecule prescribed at treatment start and/or AD molecules different from the initial one during follow-up). HRU (GPs and specialists visits and co-prescriptions) and SL registrations (due to any cause, due to psychiatric/neurologic reasons, and MDD-related respectively for German GPs, German specialists, and Spanish panels) during follow-up were analysed by group of AD therapeutic approach RESULTS: 8,891, 1,685, and 1,817 patients were respectively selected from German GPs, German specialists, and Spanish GPs/specialists panels. ADMONO approach was the most frequent for all the three cohorts. ADCOM patients had more visits requests and concomitant drugs prescriptions compared to ADMONO ones. Moreover, SL registrations were more frequently recorded for ADCOM patients. In particular, patients with 31+ days of SL were 44% and 28% respectively for ADCOM and ADMONO in the German GPs cohort, 23% and 12% respectively for ADCOM and ADMONO in the German specialists cohort, and 16% and 4% respectively for ADCOM and ADMONO in the Spanish cohort CONCLUSIONS: Results from this study reflect different perspectives on MDD patients management and consistently showed that ADMONO is associated with lower HRU and SL recording in patients with MDD
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PMH13
Topic
Economic Evaluation, Health Service Delivery & Process of Care
Topic Subcategory
Disease Management
Disease
Mental Health